Identifying Biological Markers for Severe Depression

Completed

• Conditions: Major Depressive Disorder

• Registration Number: NCT01831882
• Lead Sponsor: Stanford University

Brief Summary

The primary objective of this study is to investigate the biological components of major depression. The investigators are particularity interested in genetic variation and how it contributes to cortisol (because cortisol is higher in severe depression than mild depression or healthy controls) and how it contributes to clinical symptoms, especially suicidal ideation/behavior and psychosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-04-09
• Study First Submitted QC: 2013-04-10
• Study First Posted: 2013-04-15
• Study Start: 2013-07
• Status Verified: 2020-08
• Primary Completion: 2020-08
• Study Completion: 2020-08
• Last Update Submitted: 2020-08-19
• Last Update Posted: 2020-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genetics	1 year	Blood will be drawn for gene expression, which includes genetics and metallothionein assessments. Blood will also be drawn for later assay of immune function/measures and neurotophins, and for future studies.

Trial Locations

Locations (3)

Stanford University, Department of Psychiatry and Behavioral Sciences; 🇺🇸 Stanford, California, United States

Weill Cornell Medical College; 🇺🇸 New York, New York, United States

University of California, Irvine; 🇺🇸 Irvine, California, United States